Ibrance vs Revlimid
Side-by-side cost comparison based on Medicare Part D data
Ibrance
Palbociclib
Manufactured by Pfizer
Revlimid
Lenalidomide
Manufactured by Bristol-Myers Squibb
Ibrance costs 15% less per claim than Revlimid ($10,816.00 vs $12,786.00). A generic version of Ibrance is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Ibrance | Revlimid |
|---|---|---|
| Avg Cost Per Claim | $10,816.00 | $12,786.00 |
| Total Medicare Spending | $4.5B | $7.8B |
| Total Beneficiaries | 36,000 | 58,000 |
| Total Claims | 418,000 | 612,000 |
| Annual Cost/Patient | $125,583.00 | $134,914.00 |
| Year-over-Year Change | -5.6% | -3.4% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Mar 15, 2027 |
| Manufacturer | Pfizer | Bristol-Myers Squibb |
| Condition | Cancer | Cancer |
| Generic Name | Palbociclib | Lenalidomide |
Ibrance vs Revlimid: What the Data Shows
Ibrance (Palbociclib) and Revlimid (Lenalidomide) are both used to treat cancer. Based on Medicare Part D data, Ibrance costs $10,816.00 per claim, which is 15% less than Revlimid at $12,786.00 per claim.
Medicare spent $4.5B on Ibrance and $7.8B on Revlimid. In terms of patient reach, Revlimid serves more beneficiaries (58,000 vs 36,000).
Year-over-year spending changed -5.6% for Ibrance and -3.4% for Revlimid.
Ibrance has a generic available, while Revlimid remains brand-only until its patent expires Mar 15, 2027.
Frequently Asked Questions
Ibrance is cheaper at $10,816.00 per claim, compared to $12,786.00 for Revlimid. That makes Ibrance about 15% less expensive per claim based on Medicare Part D data.
Yes, both Ibrance and Revlimid are used to treat cancer. Your doctor can help determine which medication is more appropriate for your specific situation.
Ibrance has a generic version (Palbociclib) available, which is typically much cheaper. Revlimid is currently brand-only, with patent expiring Mar 15, 2027.
Medicare Part D spent $4.5B on Ibrance covering 36,000 beneficiaries, and $7.8B on Revlimid covering 58,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.